We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Amgen Inc | NASDAQ:AMGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -3.23 | -1.20% | 266.15 | 3,610 | 14:06:51 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 266.40 | 267.00 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 28.19B | 6.72B | 12.5336 | 21.49 | 144.37B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 14:13:02 | 4 | 266.73 | USD |
| Date | Time | Source | Headline |
|---|---|---|---|
| 10/1/2024 | 15:12 | DJN | Xeris Biopharma Shares Climb 12% on Amgen License Agreement |
| 10/1/2024 | 13:53 | DJN | Xeris Biopharma Reaches License Agreement With Amgen On Thyroid Eye Disease.. |
| 10/1/2024 | 13:45 | IHNW | GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons |
| 02/1/2024 | 16:42 | DJN | Amgen On Pace for Record High Close -- Data Talk |
| 14/12/2023 | 14:53 | DJN | Amgen Names James Bradner Chief Scientific Officer |
| 13/12/2023 | 21:40 | DJN | Amgen Gets FDA Priority Review For Lung Cancer Treatment |
| 12/12/2023 | 21:41 | DJN | Amgen Raises Dividend 5.6% To $2.25 A Share |
| 01/11/2023 | 12:45 | IHNW | Get Ready for Next Generation of Diabetes, Weight-Management Drugs |
| 31/10/2023 | 23:35 | DJN | Amgen Gets FDA Approval for Inflammatory Diseases Treatment |
| 31/10/2023 | 14:43 | DJN | Amgen on Pace for Largest Percent Decrease Since September 2022 -- Data.. |
Amgen (AMGN) Share Charts1 Year Amgen Chart |
|
1 Month Amgen Chart |
Intraday Amgen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
